

What is claimed is:

1. Compound **1,** or a pharmaceutically acceptable salt thereof,



Compound **1**


in combination with an effective amount of Compound **2,** or a pharmaceutically acceptable salt thereof,



Compound 2


for use in the treatment of HCV or a condition resulting from a hepatitis C infection, in a human in need thereof**.**

2. Use of Compound **1,** or a pharmaceutically acceptable salt thereof,



Compound **1**


in combination with an effective amount of Compound **2,** or a pharmaceutically acceptable salt thereof,



Compound 2

in the manufacture of a medicament for the treatment of HCV or a condition resulting from a hepatitis C infection.

3. The combination for use or use of claim 1 or 2, wherein Compound **1** is Compound **1-A**




**Compound 1-A**.

4. The combination for use or use of any one of claims 1 to 3, for oral administration.
5. The combination for use or use of any one of claims 1 to 3, for parenteral administration.
6. The combination for use or use of claim 5, for intravenous administration.
7. The combination for use or use of any one of claims 1-6, wherein the condition resulting from a hepatitis C infection is selected from the group consisting of viral-based chronic liver inflammation, liver cancer resulting from advanced hepatitis C (hepatocellular carcinoma (HCC)), cirrhosis, chronic or acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C and anti-HCV-based fatigue.
8. The combination for use or use of any one of claims 1-7, comprising from about 100 mg to about 800 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof.


9. The combination for use or use of any one of claims 1-8, comprising at least about 550 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof.
10. The combination for use or use of any one of claims 1-9, comprising from about 90 to about 360 mg of Compound 2 or a pharmaceutically acceptable salt thereof.
11. The combination for use or use of any one of claims 1-10, comprising at least about 180 mg of Compound 2 or a pharmaceutically acceptable salt.
12. The combination for use or use of any one of claims 1-11, wherein the combination is in a single dosage form.
13. The combination for use or use of any one of claims 1-12, comprising a dosage form comprising Compound 1, or a pharmaceutically acceptable salt thereof, and a second dosage form comprising Compound 2, or a pharmaceutically acceptable salt thereof.
14. The combination for use or use of any one of claims 1-13, wherein the combination is administrable toa cirrhotic patient.
15. The combination for use or use of any one of claims 1-13, wherein the combination is administrable to a non-cirrhotic patient.
16. The combination for use or use of any one of claims 1-15, for about once per day administration.
17. The combination for use or use of any one of claims 1-16, for about twice per day administration.
18. The combination for use or use of any one of claims 1-17, for administration for up to about 12 weeks.
19. The combination for use or use of any one of claims 1-17, for administration for up to about 8 weeks.
20. The combination for use or use of any one of claims 1-17, for administration for up to about 6 weeks.
21. The combination for use or use of any one of claims 1-17, for administration for up to about 4 weeks.
22. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 1.

23. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 2.
24. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 3.
25. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 4.
26. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 5.
27. The combination for use or use of any one of claims 1-21, wherein the HCV infection is genotype 6.
28. The combination for use or use of any one of claims 22-27, wherein the HCV is a resistance associated mutant.
29. A pharmaceutical combination comprising Compound **1** or a pharmaceutically acceptable salt thereof:



Compound **1**

and Compound **2**, or a pharmaceutically acceptable salt thereof:



Compound 2

wherein Compound 1 and Compound 2 are in the same dosage form or different dosage forms.


30. The pharmaceutical combination of claim 29, wherein the combination is in a single dosage form.
31. The pharmaceutical combination of claim 29, wherein the combination is in two or more dosage forms.
32. The pharmaceutical combination of claim 31, wherein one dosage form in the combination comprises Compound 1 or a pharmaceutically acceptable salt thereof and the second dosage form in the combination comprises compound 2 or a pharmaceutically acceptable salt thereof.
33. The pharmaceutical combination of claim 31, wherein both dosage forms comprise Compound 1 or a pharmaceutically acceptable salt thereof and Compound 2 or a pharmaceutically acceptable salt thereof.
34. The pharmaceutical combination of any one of claims 29-33, comprising from about 100 mg to about 800 mg of Compound 1 or an equivalent amount of a pharmaceutically acceptable salt thereof.
35. The pharmaceutical combination of any one of claims 29-34, comprising about 550 mg of Compound 1 or an equivalent amount of a pharmaceutically acceptable salt thereof.
36. The pharmaceutical combination of any one of claims 29-35, comprising about 150 to 200 mg of Compound 2 or an equivalent amount of a pharmaceutically acceptable salt thereof.
37. The pharmaceutical combination of any one of claims 29-36, comprising at least about 180 mg of Compound 2 or a pharmaceutically acceptable salt thereof.
38. The pharmaceutical combination of any one of claims 29-36, wherein the composition is in a dosage form suitable for oral delivery.
39. The pharmaceutical combination of any one of claims 29-36, wherein the composition is in a formulation suitable for parenteral delivery.
40. The pharmaceutical combination of claim 39, wherein the composition is in a formulation suitable for intravenous delivery.
41. The pharmaceutical combination of any one of claims 29-40, further comprising a pharmaceutically acceptable carrier.

42. The pharmaceutical combination of claim 41, wherein the carrier is a lubricant, a granulating agent, a binder, a disintegrating agent, a sugar carrier or a starch.

43. The pharmaceutical combination of claim 42, wherein the carrier is selected from the group consisting of mannitol, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and silicified microcrystalline cellulose.


44. The pharmaceutical combination of any one of claims 29-38 or 41-43, in the form of a pill, tablet, or capsule.

45. A solid dosage form comprising Compound **1,** or a pharmaceutically acceptable salt thereof,



Compound **1**


in combination with a solid dosage form comprising Compound **2,** or a pharmaceutically acceptable salt thereof,



Compound 2


for use to treat HCV or a condition resulting from a hepatitis C infection, in a human in need thereof**.**

46. Use of a solid dosage form comprising Compound **1,** or a pharmaceutically acceptable salt thereof,



Compound **1**


in combination with a solid dosage form comprising Compound **2,** or a pharmaceutically acceptable salt thereof,



Compound 2

in the manufacture of a medicament for the treatment of HCV or a condition resulting from a hepatitis C infection.

47. The combination for use or use of claim 45 or 46, wherein Compound **1** is Compound **1-A**



**Compound 1-A**.

48. The combination for use or use of any one of claims 45-47, for oral administration.

49. The combination for use or use of any one of claims 45-48, wherein the condition resulting from a hepatitis C infection is selected from the group consisting of viral-based chronic liver inflammation, liver cancer resulting from advanced hepatitis C

(hepatocellular carcinoma (HCC)), cirrhosis, chronic or acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C and anti-HCV-based fatigue.

50. The combination for use or use of any one of claims 45-49, wherein the solid dosage form comprising Compound 1, or a pharmaceutically acceptable salt thereof, comprises from about 100 mg to about 800 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof.
51. The combination for use or use of any one of claims 45-50, wherein the solid dosage form comprising Compound 1, or a pharmaceutically acceptable salt thereof, comprises about 550 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof.
52. The combination for use or use of any one of claims 45-51, wherein the solid dosage form comprising Compound 2 comprises from about 90 to about 360 mg of Compound 2 or a pharmaceutically acceptable salt thereof.
53. The combination for use or use of any one of claims 45-52, wherein the solid dosage form comprising Compound 2 comprises about 180 mg of Compound 2 or a pharmaceutically acceptable salt.
54. The combination for use or use of any one of claims 45-53, wherein the combination is administrable to a cirrhotic patient.
55. The combination for use or use of any one of claims 45-53, wherein the combination is administrable toa non-cirrhotic patient.
56. The combination for use or use of any one of claims 45-55, wherein the combination is for use about once per day.
57. The combination for use or use of any one of claims 45-55, wherein the combination is for use about twice per day.
58. The combination for use or use of any one of claims 45-57, wherein the combination is for use for up to about 12 weeks.
59. The combination for use or use of any one of claims 45-57, wherein the combination is for use for up to about 8 weeks.
60. The combination for use or use of any one of claims 45-57, wherein the combination is for use for up to about 6 weeks.

61. The combination for use or use of any one of claims 45-57, wherein the combination is for use for up to about 4 weeks.
62. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 1.
63. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 2.
64. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 3.
65. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 4.
66. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 5.
67. The combination for use or use of any one of claims 45-61, wherein the HCV infection is genotype 6.
68. The combination for use or use of any one of claims 62-67, wherein the HCV is a resistance associated mutant.